On the 19th of March, Orbimed Advisors sold 33 thousand Oric Pharmaceuticals, Inc. (ORIC) shares for $863 thousand at an average price of $26.21 per share.
Shares of Oric Pharmaceuticals, Inc. are up 7.22% since the transaction.
Orbimed Advisors’s holding in Oric Pharmaceuticals, Inc. decreased to about 2.4 million shares with the transaction.
Orbimed Advisors first bought Oric Pharmaceuticals, Inc. stock in the second quarter of 2020.
Orbimed Advisors also owns Arcutis Biotherapeutics, Inc. (NASDAQ:), Biogen Inc (NASDAQ:), Eledon Pharmaceuticals, Inc. (ELDN) and Neurocrine Biosciences Inc (NASDAQ:).
Oric Pharmaceuticals, Inc. is its number sixteen position by number of shares and market value among pharmaceuticals stocks.
Contrary to Orbimed Advisors, Alkeon Capital Management, California State Teachers Retirement System, and Citigroup (NYSE:) added to ORIC shares.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.